GENSIGHT BIOLOGICS S.A. (EPA:SIGHT) | WebDisclosure

Basculer en Français

10372	Companies
216173	Keywords
145882	Articles
114461	Press releases

Headlines Articles Press releases GENSIGHT BIOLOGICS S.A.

Home
Companies
GENSIGHT BIOLOGICS S.A.

PRESS RELEASE

published on 09/23/2024 at 19:36, 1 year 7 months ago

Informations privilégiées / Communiqué sur comptes, résultats
GenSight Biologics publie ses résultats financiers du premier semestre 2024 avec une réduction des dépenses opérationnelles de 60% et l'extension de son horizon de trésorerie. Nouveau Directeur Administratif et Financier nommé

Résultats Financiers GenSight Biologics Directeur Administratif Et Financier Dépenses Opérationnelles Horizon De Trésorerie
BRIEF

published on 09/17/2024 at 14:45, 1 year 7 months ago

Goldman Sachs vend ses actions GENSIGHT BIOLOGICS S.A.

Euronext Paris Franchissement De Seuils Goldman Sachs Cession D'actions GenSight Biologics
BRIEF

published on 09/17/2024 at 14:45, 1 year 7 months ago

Goldman Sachs sells its GENSIGHT BIOLOGICS SA shares

Euronext Paris Goldman Sachs Crossing Thresholds Transfer Of Shares GenSight Biologics
PRESS RELEASE

published on 09/17/2024 at 14:40, 1 year 7 months ago

Franchissement de seuils
Déclaration de franchissement de seuils par The Goldman Sachs Group, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris

Euronext Paris Déclaration The Goldman Sachs Group Franchissement De Seuils GenSight Biologics
BRIEF

published on 07/23/2024 at 07:35, 1 year 9 months ago

GenSight Biologics Reports Financial Position and Business Progress

Gene Therapy Financial Update GenSight Biologics LUMEVOQ Early Access Program
BRIEF

published on 07/23/2024 at 07:35, 1 year 9 months ago

GenSight Biologics présente sa situation financière et ses progrès commerciaux

Thérapie Génique Mise À Jour Financière Produits Biologiques GenSight LUMEVOQ Programme D'accès Anticipé
PRESS RELEASE

published on 07/23/2024 at 07:30, 1 year 9 months ago

Inside Information / News release on accounts, results
GenSight Biologics reports cash position of €6.9 million as of June 30, 2024, with potential over 100 vials available upon Q3 resumption of early access program. Company confirms sufficient working capital and successful blending step for LUMEVOQ drug product

Working Capital Business Update Cash Position GenSight Biologics LUMEVOQ Drug Product
PRESS RELEASE

published on 07/23/2024 at 07:30, 1 year 9 months ago

Informations privilégiées / Communiqué sur comptes, résultats
GenSight Biologics publie sa position de trésorerie au 30 juin 2024, et fait le point sur ses activités. La trésorerie s'élève à 6,9 millions d'euros, suffisante jusqu'au quatrième trimestre 2024

Trésorerie GenSight Biologics Thérapies Géniques Activités LUMEVOQ
BRIEF

published on 07/11/2024 at 07:35, 1 year 9 months ago

GenSight Biologics Launches Newsletter for Retail Investors

Financial Updates Gene Therapy Retail Investors LUMEVOQ® Optogenetics
BRIEF

published on 07/11/2024 at 07:35, 1 year 9 months ago

GenSight Biologics lance une newsletter destinée aux investisseurs particuliers

Investisseurs Particuliers Thérapie Génique LUMEVOQ® Optogénétique Mises À Jour Financières

Accesswire

Published on 05/09/2026 at 01:55, 21 hours 17 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 21 hours 32 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 21 hours 42 minutes ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 23 hours 12 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 1 day ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/09/2026 at 19:05, 4 hours 6 minutes ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 2 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 3 hours ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 4 hours ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 1 day 4 hours ago

Designated Person Notification

Les Echos

Published on 05/07/2026 at 19:15, 2 days 3 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 3 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 4 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 4 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 4 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE